scholarly journals Seven Years Maintenance Cost of Implant-Retained Overdentures on Ball Versus Locator ® Abutments.

2020 ◽  
Author(s):  
Jan D'haese ◽  
Carine Matthys ◽  
Hamed Sahak ◽  
Jos Besseler ◽  
Hugo De Bruyn
Keyword(s):  
Quality Of Life ◽  
Initial Treatment ◽  
Treatment Cost ◽  
Maintenance Cost ◽  
Maintenance Costs ◽  
Total Cost ◽  
Initial Cost ◽  
Technical Issues ◽  
Clinical Records

Denture wearers often complain about jeopardized function and reduced quality of life due to lack of prosthesis’ retention. Implant retained mandibular overdentures, on 2 non-connected implants (2IOD) are well-proven solutions to overcome these issues. We prospectively assessed 69 patients and scrutinized clinical records until at least 7 years of function. Thirty-six were retained on Locator ® Abutments (LA) and thirty-tree on Ball Abutments (BA). Both systems were compared regarding the type, amount and total cost of required maintenance. One implants was lost, yielding 98.7% survival after 7 years. In total 438 technical issues occurred: 121 (27.35%) in BA and 317 (72.4%) in LA. Out of these, 343 events (78%) were solved chairside: 191 (43.6%) were replacements of retention caps, 113 (25.8%) were minor acrylic repairs, in 26 (5.9%) pressure ulcers had to be relieved and 13 (3%) related to abutments. LA required 179 insert replacements compared to 12 in the BA group. The overall initial treatment cost was 3850 euro. The average total maintenance cost in relation to the initial cost for the LA and BA groups was 19.11% (range 0% - 82.24%) and 18.91% (range 0% - 113.26%) respectively (P=0.540). Conclusions: The 7-years maintenance costs for a 2IOD is acceptable when the patient is regularly checked and professionally maintained. Most events are easily solvable chairside, but a few patients required more expensive interventions, regardless of the type of attachment used.

scholarly journals PCV118 Observational Study on the Treatment, Cost and Quality of Life of Subjects with Hereditary Angioedema

2011 ◽  
Vol 14 (7) ◽  
pp. A386
Author(s):  
L. Bouillet ◽  
V. Montauban ◽  
K. Finck ◽  
V. Jeanbat ◽  
S. Bouee
Keyword(s):  
Quality Of Life ◽  
Observational Study ◽  
Hereditary Angioedema ◽  
Treatment Cost

VP21 Factors Associated With Recommendations On Drugs For Rare Diseases

2018 ◽  
Vol 34 (S1) ◽  
pp. 164-164
Author(s):  
Fernanda Inagaki Nagase ◽  
Jian Sun ◽  
Tania Stafinski ◽  
Devidas Menon
Keyword(s):  
Quality Of Life ◽  
Rare Diseases ◽  
External Validity ◽  
Treatment Cost ◽  
Orphan Drugs ◽  
Clinical Safety ◽  
Factors Associated ◽  
Drug Review ◽  
Positive Recommendation

Introduction:In Canada, reimbursement recommendations on drugs for common and rare indications (for example, orphan drugs) are made through the pan-Canadian Oncology Drug Review (pCODR) and the Common Drug Review (CDR). However, some stakeholders have called for a separate mechanism for orphan drugs, arguing that existing processes place too much weight on their high price tags. The purpose of this study was to examine factors associated with positive recommendations on drugs for rare diseases.Methods:Information was extracted from CDR and pCODR recommendations on drugs for diseases (prevalence of less than 1 in 2,000) up to April 2018. Univariate and multivariate logistic regression models were applied to explore the influence of the following variables on recommendations: year; prevalence; clinical safety and effectiveness (safety, quality of life, symptoms, surrogate outcomes, and survival); quality of evidence (availability of comparative data, external validity, and bias); unmet need; treatment cost; and incremental cost-effective ratio (ICER). Two-way interactions were also tested.Results:Of 128 recommendations, fifty-four (77 percent) and forty (69 percent) were positive for cancer and non-cancer indications, respectively. For cancer indications, all submissions reporting meaningful improvements in surrogate, quality of life, and survival outcomes were significantly more likely to have a positive recommendation. Submissions showing a lack of external validity were significantly less likely to receive a positive recommendation. For non-cancer indications, more recent submissions and those presenting no safety issues were associated with positive recommendations. Prevalence, treatment cost, and ICER were not determinants of positive or negative recommendations.Conclusions:For both cancer and non-cancer orphan drugs, impact on clinical safety and effectiveness, rather than cost, appears to be a key factor in the formulation of recommendations.

An assessment of the total cost of pancreatic cancer using real-world evidence.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 773-773
Author(s):  
Vincent J. Picozzi ◽  
Victoria G. Manax ◽  
Kelly Feehan ◽  
Zachary Wintrob ◽  
Michele Korfin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Prescription Drug ◽  
Cancer Care ◽  
Drug Costs ◽  
Medical Expenditure ◽  
Total Cost ◽  
Patient Level ◽  
Second Year

773 Background: The aggregate health economic implications of pancreatic cancer are poorly understood, especially from the patient perspective. As a preliminary effort, we sought to better understand changes in type and quantity of medical expenditures over time, along with quality of life related costs, from this perspective. This preliminary research is part of a larger effort to understand how the introduction of new treatments affect both the outcome and costs of pancreatic cancer associated with care, patients, survivors, their families, and their communities. Methods: We analyzed patient-level data from the Medical Expenditure Panel Survey (MEPS, 1996- 2017). All analyses were performed using R version 3.6.1 on Ubuntu 19.04. Averages were computed for the total health care costs, including prescription drug costs. Average individual annual cost estimates for the second year excluded individuals that were identified as having died prior to the first round of data collection in the second year. The individual patient level ratios of prescription drug cost to other medical expenses was also computed. All expenditures are adjusted for inflation using 2017 US dollars. Included subjects, N= 80 had a diagnosis of pancreatic cancer and available prescription data. Individual age and employment status were accounted for as covariates. Results: Between 1997 and 2017 inflation adjusted first and second year non-medication spending on pancreatic cancer care averaged $66,999.96 and $105,308.60 respectively. However, inflation-adjusted first and second year charges for hospitalizations and emergency visits fell between 2007-2017. Prescription drug as a proportion of total spending prescription drugs increased during the same time period. Lost work/school days declined between 2007 and 2017. Conclusions: Total inflation adjusted pancreatic cancer care expenses declined over the past decade even as drug costs increased. Quality of life costs declined as well. Further analysis is needed to evaluate the relationship between drug spending, total cost of care and quality of life.

Silicone Rubber—A Perspective

1976 ◽  
Vol 49 (4) ◽  
pp. 909-936 ◽  
Author(s):  
E. L. Warrick
Keyword(s):  
Quality Of Life ◽  
Silicone Rubber ◽  
Standard Of Living ◽  
Unique Role ◽  
Initial Cost ◽  
Technological Advances ◽  
Physical Wellbeing ◽  
Polydimethylsiloxane Elastomer ◽  
Better Than

Abstract Silicone rubber began as a polydimethylsiloxane elastomer vulcanized by benzoyl peroxide. Today, 33 years after its discovery, silicone rubber is a line of products of widely different compositions and vulcanized by many different systems. Our knowledge of the rubber is far better than it was but it is by no means complete. Applications are many, but in general, they are in vital areas where extreme environmental conditions will not permit the use of any other material. Service life cost is usually lower than for other rubbers, despite higher initial cost. Uses in surgery fulfill a unique role in saving lives or improving the quality of life for many. Dr. R. R. McGregor said of the field of silicones, in general, “What had been started as a search for further knowledge proved to be the groundwork for technological advances that have proved helpful to industry, and in so doing, have contributed to improving our standard of living”. What he said of silicones as a whole, certainly applies to silicone rubber, and I have been happy to have contributed to the knowledge of silicone rubber and to have been a part of these advances which, in addition, contribute to our physical wellbeing by their use in the human body. These remarks are not in any way an epitaph for silicone rubber, but rather, they are the opening words in a book of growing usefulness for silicone rubber for us all. The adventure has just begun.

Surgery of Intradural Extramedullary Tumors

Neurosurgery ◽  
2014 ◽  
Vol 75 (5) ◽  
pp. 509-514 ◽  
Author(s):  
Roberto Tarantino ◽  
Pasquale Donnarumma ◽  
Loenzo Nigro ◽  
Marika Rullo ◽  
Antonio Santoro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rating Scale ◽  
Neurological Deficits ◽  
Statistical Interpretation ◽  
Intradural Extramedullary ◽  
Examination Quality ◽  
Clinical Records ◽  
University Of Rome

Abstract BACKGROUND: Intradural extramedullary tumors (IDEMTs) are uncommon lesions that cause pain and neurological deficits. OBJECTIVE: To evaluate the effects of surgery for IDEMTs. METHODS: This cohort study recruited all patients operated on for IDEMTs at the Department of Neurology and Psychiatry of Sapienza University of Rome from January 2003 to January 2013. The analysis was conducted on clinical records evaluation over a 1-year follow-up. The Graphic Rating Scale was used to assess pain. Neurological deficits were detected through neurological examination. Quality of life was evaluated with the EuroQol (EQ-5D). Statistical interpretation of the data was performed with SPSS version 19 software. RESULTS: One hundred seven patients were recruited. Three were lost to follow-up. Patients reported lower level of pain 1 year after surgery (before surgery, 6.05; after surgery, 3.65). Mean comparison showed a significant decrease of −2.400 (P < .001). Ninety-two patients (88.5%) were neurologically asymptomatic 1 year after surgery. Only 12 patients (11.5%) presented with a deficit, with a global decrease of 39% (χ2 = 27.6; P < .005). The quality of life in patients was middle to high (mean rating of EQ-5D visual analog score, 61.78%). The lowest levels of quality of life were found in patients with sphincter dysfunctions (mean, 33.4). CONCLUSION: Surgery for IDEMTs has a good outcome. Patients reported lower levels of pain and a drastic reduction in neurological symptoms 1 year after surgery. The quality of life is middle to high. It is influenced mainly by the neurological outcome.

Sign in / Sign up

Export Citation Format

Share Document